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INTRODUCTION
Herpes simplex virus type 1 (HSV-1) is a member of the
herpesvirsus family, which infection commonly involves
recurrent mucocutaneous manifestations (1). HSV-1 could
also cause illness in a much severe form; ocular herpes could
cause adult blindness, furthermore induce sporadic encephalitis,
usually resulting in severe morbidity or mortality (2). More-
over, HSV-1 is one of the leading infectious viral pathogens
found in immunocompromised hosts, such as transplant recip-
ients. HSV-1-induced tissue damage comprises of mononu-
clear cell infiltration, perivascular inflammation, as well as
various cytopathogenic changes including intracellular inclu-
sion bodies and syncytial formation (3). Especially, syncytial
formation is a characteristic pathologic response seen in her-
pesvirus or human immunodeficiency virus type 1 (HIV-1)
infections (3, 4).
This fusogenic activity in HSV-1-infected cells requires
the presence of specific glycoproteins in the virion envelope,
including glycoprotein B (gB), gD, gH, and gL (5-8). Syn-
cytial formation starts with the binding of virus-infected
cells to uninfected cells through viral glycoprotein-receptor
interaction, followed by cell-to-cell fusion to form a multin-
ucleated giant cell, the syncytium. This eventually ruptures
to cause cell death. It is noteworthy that patients infected
with syncytium-inducing (SI) HIV-1 variants have a more
rapid deterioration in their course than those infected with
non-SI variants (9, 10).
In immunocompromised hosts infected with HSV-1, con-
current infections by other microorganisms, including other
viruses are not uncommon. Human cytomegalovirus (HCMV)
is another important causal agent in opportunistic infection,
which can induce comparable cytopathogenic effects in infect-
ed cells (11). There have been numerous reports of co-infec-
tion of HSV-1 and HCMV in immunocompromised patients
(12-14). The clinical outcome of herpesvirus co-infection is
most appreciated in follow-up studies after transplantation.
For example, grafts infected with both HSV-1 and HCMV
results in shorter graft and patient survival than grafts with
either single viral infection (14). However, there are no study
yet which investigates the pathology in HSV-1, HCMV co-
infected tissue or organs.
We hypothesized that in the setting of active HSV-1 and
HCMV co-infection, HCMV could exacerbate HSV-1-induced
cytopathogenic changes in HSV-1 permissive cells. In par-
ticular, we focused on the HCMV gene products from the
major immediate early (IE) gene. By utilizing a U373MG
cell line expressing HCMV IE1 protein (15), we investigat-
ed the function of HCMV IE1 protein in modulating HSV-
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Human Cytomegalovirus IE1 Protein Enhances Herpes Simplex Virus
Type 1-induced Syncytial Formation in U373MG Cells
Co-infection of herpes simplex virus type 1 (HSV-1) and human cytomegalovirus
(HCMV) is not uncommon in immunocompromised hosts. Importantly, organ trans-
plant recipients concurrently infected with HSV-1 and HCMV have a worse clinical
outcome than recipients infected with a single virus. However, factors regulating
the pathologic response in HSV-1, HCMV co-infected tissues are unclear. We investi-
gated the potential biologic role of HCMV gene product immediate early 1 (IE1) pro-
tein in HSV-1-induced syncytial formation in U373MG cells. We utilized a co-infec-
tion model by infecting HSV-1 to U373MG cells constitutively expressing HCMV
IE1 protein, UMG1-2. Syncytial formation was assessed by enumerating nuclei
number per syncytium and number of syncytia. HSV-1-induced syncytial formation
was enhanced after 24 hr in UMG1-2 cells compared with U373MG controls. The
amplified phenotype in UMG1-2 cells was effectively suppressed by roscovitine in
addition to inhibitors of viral replication. This is the first study to provide histological
evidence of the contribution of HCMV IE1 protein to enhanced cytopathogenic
responses in active HSV-1 infection.
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MATERIALS AND METHODS
Cell lines and virus
We utilized cell line UMG1-2 that constitutively expresses
HCMV IE1 protein in U373MG cells (ATCC HTB 17)
(15). U373MG cells transfected with the empty retrovirus
vector LNCX2 vector (Clontech, Palo Alto, CA, U.S.A.) was
used as the control. Cells were cultured in Dulbecco’s modi-
fied Eagles medium (GIBCO, Grand Island, NY, U.S.A.)
with 10% fetal bovine serum (GIBCO), 100 U/mL penicillin
and 100 U/mL streptomycin (Life Technologies, Carlsbad,
CA, U.S.A.) in a 37℃ incubator with 5% CO2. HSV-1 Mac-
Intyre (ATCC VR-539) was used in the experiment. 
Reagents
Neutralizing anti-HSV-1 monoclonal antibody, MHSVI116
(2 μ g/mL) was used as previously described (16). Other rea-
gents were used in the following concentration: ganciclovir
(40 μ M), mitomycin C (1 μ g/mL), nocodazole (10 μ g/mL),
N-tosyl-1-phenylalanine-chloromethyl ketone (TPCK) (10,
100 μ M), emodin (1, 10 μ M) and roscovitine (2-100 μ M).
All reagents were purchased from Sigma (St. Louis, MO,
U.S.A.). Concentrations of the drugs were determined by
appraisal of former reports of drug treatment in U373MG
cells or in studies utilizing HSV-1 (15, 17-19). Drugs were
prepared in 100× concentrations.
HSV-1 infection and syncytial formation 
Ten thousand cells were plated on each compartment of
an 8-chamber slide (Sigma) and cultured for 24 hr. HSV-1
stock (2.0×106 plaque forming unit/mL) was diluted 10
fold from 10-1 to 10-4 in volume. UMG1-2 and its control
in each compartment were infected with 100 μ L of HSV-1
for 1 hr followed by washing phosphate-buffered saline (PBS)
and addition of 100 μ L of media. Slides were fixed with 4%
paraformaldehyde-PBS after 6, 12, 24, 48, and 72 hr and
stained with hematoxylin & eosin. The size of each syncytium
was evaluated by visible nuclei numbers per syncytium under
a light microscope (8). Syncytium with 5 or more nuclei was
enumerated in five low-power fields. Experiments were repeat-
ed three times.
Immunohistochemistry 
Cells were infected with 0.2 multiplicity of infection (m.o.i.)
of HSV-1 for 1 hr and were added with media after washing
with PBS. Immunohistochemistry was done with the follow-
ing protocol; cells were fixed with 4% paraformaldehyde-
PBS for 1 hr and then permeabilized with 0.5% Nonidet P-
40 (Sigma)-PBS for 5 min. After washing, wells were blocked
with 2% skim milk for 30 min, and then treated with MH-
SVI116 antibody for 1 hr at room temperature. Peroxidase-
conjugated anti-mouse IgG (Jackson Immunoresearch, West
Grove, PA, U.S.A.) in 2% skim milk was added for 1 hr at
room temperature. Finally, wells were treated with 0.2%
diaminobenzidine (Sigma) and 0.005% hydrogen peroxide
in PBS for 20 min. Reaction was stopped with distilled water
and the plates were observed under an inverted microscope.
Drug treatment
Cells were concomitantly treated with the drug of inter-
est with HSV-1 infection (0.2 m.o.i.). Culture media with
or without dimethyl sulfoxide (DMSO, Sigma) was used as
controls. After infecting cells with HSV-1 for 1 hr, cells were
washed with PBS, and then each drug concentration was
maintained for 24 hr. Cells were fixed and immunohisto-
chemistry was performed as described, followed by enumer-
ation of syncytia (nuclei ≥5) under an inverted microscope.
Experiments were repeated three times.
Statistical analysis
Prism (Version 4.00, GraphPad Software Inc., San Diego,
CA, U.S.A.) was used to evaluate the data. Student t-test
was used for comparing the number of syncytia as well as
nuclei per syncytium after HSV-1 infection. A p value <0.05
was considered to be significant. 
RESULTS
Enhanced syncytial formation in U373MG cells expressing
HCMV IE1 protein
Both UMG1-2 and U373MG control cells formed syncytia
after HSV-1 infection. Syncytial formation was negligible at
6 hr post-infection even in high HSV-1 concentrations but
noticeable at 12 hr at 2 m.o.i. (data not shown). At 24 hr, we
could appreciate a clear m.o.i.-dependent syncytial formation
by HSV-1 (Fig. 1A). The syncytial formation effect was en-
hanced in UMG1-2 cells compared with the U373MG con-
trol, especially the size of the syncytium. The nuclei number
per syncytium was significantly higher in UMG1-2 cells than
in U373MG control cells (Fig. 1B). The number of syncytia in
the two groups was not different at 2 m.o.i., as all sizes of syn-
cytia were included. With ongoing fusogenic activity in both
groups of cells, syncytia enumeration was difficult in longer
periods of infection (48, 72 hr) due to cell lysis, especially in
UMG1-2 cells in which cell lysis was detected earlier, at a
lower m.o.i. due to robust syncytial formation (data not shown). 
Drug effects on syncytial formation
For further characterization of the enhanced cytopathogenic1048 K.-C. Shin, C.-G. Park, E.-S. Hwang, et al.
changes in UMG1-2 cells, cells were treated with blocking
antibody or inhibitors pertinent to viral multiplication and
intracellular signaling associated with herpesvirus infection
(Fig. 2A). First, MHSVI116, a neutralizing antibody against
HSV-1 gB, completely abrogated syncytial formation by











































Fig. 1. Enhanced syncytial formation in HSV-1-infected UMG1-2 cells. (A) UMG1-2 and U373MG control cells were infected with HSV-1
for 24 hr on a chamber slide. Note the increased syncytial formation in UMG1-2 cells compared with U373MG controls (100× magnifi-
cation). (B) Enumeration of nuclei per syncytium and number of syncytia after 24 hr. Note the increased syncytial formation, especially
nuclei number of syncytium in UMG1-2 cells (*p<0.05, 
� p<0.01, 
� p<0.001). Values are expressed as mean±standard error and represent
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Fig. 2. Roscovitine ameliorates augmented syncytial formation in HSV-1-infected UMG1-2 cells. (A) Cells were plated on a 96-well plate
and treated with described reagents simultaneously at the time of HSV-1 infection for 24 hr. MHSVI-116, ganciclovir, mitomycin C, and
nocodazole robustly suppressed syncytial formation of both groups of cells. Roscovitine (20 μ M) also effectively inhibited syncytial for-
mation in UMG1-2 cells as well as U373MG control cells (*p<0.05, 
� p<0.01). TPCK, N-tosyl-1-phenylalanine-chloromethyl ketone. Values
are expressed as mean±standard error and represent data from 3 independent experiments. (B) Comparison of immunohistochemistry
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zole was used to impair microtubule-mediated transport of
HSV-1 capsid to the nucleus (20). It markedly suppressed
syncytial formation in both cell lines as expected. Syncytial
formation was also compromised in both cell lines by block-
ing viral DNA synthesis with ganciclovir or mitomycin C.
After treatment of cyclin-dependent kinase (cdk) inhibitor
roscovitine, both UMG1-2 and U373MG controls showed
decreased syncytial formation (Fig. 2B). Importantly, the
enhanced cytopathogenic response in UMG1-2 was dimin-
ished by roscovitine. Moreover, nuclei numbers per syncytium
were significantly lower in both cell lines treated with roscov-
itine (media vs. roscovitine-treated UMG1-2 cells ([mean±
SD] 27.4±5.8 vs. 12.1±3.5, p=0.001). Other inhibitors
such as tyrosine kinase inhibitor, emodin, and NF-κ B in-
hibitor, TPCK, did not suppress syncytial formation in either
cell lines after infection.
Dose-dependent inhibition of syncytial formation by
roscovitine 
To further investigate the dose response of roscovitine in
HSV-1-infected cells, we next compared syncytial forma-
tion in different concentrations of roscovitine (Fig. 3). Roscovi-
tine inhibited syncytial formation in both HSV-1-infected
cells in a dose-dependent manner at 24 hr post-infection.
With increase concentration of roscovitine, enhanced syncy-
tial formation in HSV-1-infected UMG1-2 cells was effec-
tively neutralized. 
DISCUSSION
HSV-1 infection with co-infection with other viruses, could
cause severe illness in immunocompromised hosts (14). By
utilizing a HSV-1 permissive U373MG cell line constitutive-
ly expressing HCMV IE1 protein, we demonstrated enhanced
syncytial formation in IE1 protein expressing UMG1-2 cells
after HSV-1 infection. Furthermore, we showed that along
with potent viral replication inhibitors and neutralizing anti-
bodies, roscovitine could effectively inhibit the augmented
the cytopathogenic effect. To better control the variability
produced by the complex biology of co-infection models,
we postulated that HCMV major IE gene products could
be a major factor modulating HSV-1 pathogenecity in host
cells co-infected with both herpesviruses. This hypothesis
was supported by in vitro studies demonstrating HSV-2
reactivation by HCMV in the very early stages of HCMV
super-infection (21, 22).
HCMV IE1 protein, one of the two (IE1 and IE2) tran-
scription factors of the major IE promoter, is the most abun-
dantly expressed viral protein in the immediate early phase
of HCMV-infected permissive human cell lines (23, 24).
HCMV IE1 protein is expressed shortly after HCMV infec-
tion and its level increases steadily through 72 hr (25). More-
over, HCMV infection induces dominant expression of IE1
protein compared with IE2 protein in many cancer cell lines
such as Saos-2 and U373MG (15). In fact, HCMV IE1 pro-
tein helps expression of viral and cellular promoters syner-
gistically with IE2 protein (26). Interactions have been report-
ed between HCMV IE1 protein and other transcription fac-
tors, such as SP-1 and CTF-1, or the TFIID complex (27-
29). Especially, HCMV IE1-TFIID interaction leads to inhi-
bition of apoptosis induced by tumor necrosis factor in vitro
(30, 31).
The functional role of HCMV IE1 protein in host cell
growth has been previously described in several transfection
studies (32-35). HCMV IE1 protein was first known to inter-
act with retinoblastoma susceptibility gene-related p107 pro-
tein to overcome p107-induced cellular growth arrest (33,
34). Subsequent studies revealed that HCMV IE1 but not
IE2 protein, could bind to p107 and facilitate cyclinE/cdk2
activation (35). Furthermore, HCMV IE1 protein induces
resistance to apoptosis in U373MG cells by cdk2 accumula-
tion (15). Cdks are required for replication of many viruses,
including HIV-1, HSV-2, HCMV, and varicella-zoster virus
(36-40). Among pharmacological cdk inhibitors, roscovi-
tine has already been investigated as a potential anticancer
drug for disrupting the cell cycle (41). The emerging inter-
est in roscovitine is its antiviral effect, such that it specifically
inhibits genes in viruses such as HIV-1, HSV-2, HCMV, and
varicella-zoster virus (42, 43). In HSV-1-infected cells, roscov-
itine blocks accumulation of mRNAs encoding specific viral
IE and early genes, inhibits viral DNA synthesis, and alters
posttranslational modification of HSV-1 IE protein (38, 44-
47). In general, roscovitine is likely to inhibit HSV-1-induced
syncytial formation by interfering viral replication. Consid-
ering the significant reduction in syncytial size, we further
speculate roscovitine may also have affected late expression
of viral proteins, including viral glycoproteins necessary for
Fig. 3. Dose-dependent inhibition of syncytial formation by roscov-
itine. Syncytial formation in both groups of cells are suppressed
with an increasing dose of roscovitine. Note the enhanced syn-
cytial formation in UMG1-2 cells is suppressed to the level of
U373MG controls at concentrations 20 μ M or more (*p<0.05).
Values are expressed as mean±standard error and represent
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syncytial formation. 
Inhibitors of NF-κ B, and tyrosine kinsase we used did not
affect syncytial formation in HCMV IE1 protein expressing
cells. Interestingly, previous studies showed that HCMV IE1
protein selectively induce both NF-κ B complexes and its
activity (48-50). In addition, HSV-1 infection also results in
intranuclear translocation of NF-κ B (51). However, our results
show that NF-κ B signaling is not the major pathway that
HCMV IE1 protein contributes to the phenotype of enhanced
syncytial formation by HSV-1. As for the tyrosine kinase
inhibitor, emodin, we were unable to detect any evidence of
emodin affecting syncytial formation, in spite of reported
antiviral effects (19, 52). 
There are yet limitations to indicate HCMV IE1 protein
to be the essential molecule in vivo modulating increased
cytopathogenecity in HCMV, HSV-1 co-infected cells. Our
model is based on the constitutive expression of HCMV IE1
protein in host cells, disregarding the life cycle and other
gene products of HCMV. Furthermore, previous in vitro stud-
ies demonstrate functional conservation in viral gene prod-
ucts of both HCMV and HSV-1 (53-55). Thus, it is possi-
ble that other HCMV gene products could also potentiate
cytopathogenicity induced by HSV-1, especially by facili-
tating viral replication (56). Further investigations will include
identifying genes modulated by HCMV IE1 in the syncytium,
especially genes in viral glycoprotein synthesis. 
In summary, this is the first study to implicate the poten-
tial contribution of HCMV IE1 protein to enhance cytopa-
thogenic responses in active HSV-1 infection. In addition to
known potent inhibitors of viral replication, roscovitine was
able to effectively suppress HCMV IE1 protein-induced
cytopathologies, supporting its effective anti-viral activity. 
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